Lonapegsomatropin

Lonapegsomatropin, sold under the brand name Skytrofa, is a human growth hormone used for the treatment of growth hormone deficiency.^[1][3] Lonapegsomatropin is a prodrug of somatropin.^[1]

Lonapegsomatropin

Clinical data
Trade names	Skytrofa
Other names	Lonapegsomatropin-tcgd; rhGH-PEG; ACP-011; ΤransConPEG hGh; WHO-10598
License data	US DailyMed: Lonapegsomatropin
Routes of administration	Subcutaneous injection
Drug class	Growth hormone receptor agonist
ATC code	H01AC09 (WHO)
Legal status
Legal status	US: ℞-only[1][2] EU: Rx-only[3][4]
Identifiers
CAS Number	1934255-39-6
PubChem SID	381128171
DrugBank	DB16220
UNII	OP35X9610Y
KEGG	D11486
ChEMBL	ChEMBL4298185
Chemical and physical data
Formula	C1051H1627N269O317S9[C2H4O]4n

Lonapegsomatropin was approved for medical use in the United States in August 2021,^[1][2][5] and in the European Union in January 2022.^[3]

Medical uses

Lonapegsomatropin is a growth hormone therapy indicated to treat growth hormone deficiency.^[1][3]

History

The US Food and Drug Administration granted the application for lonapegsomatropin orphan drug designation.^[6]